StockData
Jazz Pharmaceuticals plc logo

Jazz Pharmaceuticals plc (JAZZ) stock

JAZZNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 2, 2026Score 7/30122% above fair value
$240.71+0.94 (+0.39%)

Close on Nov 17, 2026Market cap $15.63BP/E 78.4Yield –

Jazz Pharmaceuticals operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Jazz Pharmaceuticals's operating cash flow for the twelve months ending Sep 30, 2026 was $1.69B, up 21.6% year over year. For fiscal 2025 it was $1.36B, down 2.9% from the year before. Over ten years it grew 9.8% a year on average. The highest annual figure on record is $1.40B in fiscal 2024.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.36B-2.9%
FY2024Dec 31, 2024$1.40B+27.8%
FY2023Dec 31, 2023$1.09B-14.1%
FY2022Dec 31, 2022$1.27B+63.4%
FY2021Dec 31, 2021$778.51M-13.5%
FY2020Dec 31, 2020$899.65M+15.9%
FY2019Dec 31, 2019$776.40M-2.8%
FY2018Dec 31, 2018$798.90M+15.3%
FY2017Dec 31, 2017$693.09M+17.0%
FY2016Dec 31, 2016$592.39M+11.4%
FY2015Dec 31, 2015$531.94M+30.5%
FY2014Dec 31, 2014$407.61M+41.3%
FY2013Dec 31, 2013$288.43M+15.5%
FY2012Dec 31, 2012$249.75M+64.7%
FY2011Dec 31, 2011$151.60M+157.5%
FY2010Dec 31, 2010$58.87M–
FY2009Dec 31, 2009-$15.88M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$506.10M+6.6%
Q2 FY2026Jun 30, 2026$415.70M+368.1%
Q1 FY2026Mar 31, 2026$408.20M-5.0%
Q4 FY2025Dec 31, 2025$362.47M-9.1%
Q3 FY2025Sep 30, 2025$474.70M+19.0%
Q2 FY2025Jun 30, 2025$88.80M-73.2%
Q1 FY2025Mar 31, 2025$429.80M+60.8%
Q4 FY2024Dec 31, 2024$398.58M+138.2%
Q3 FY2024Sep 30, 2024$398.75M+29.8%
Q2 FY2024Jun 30, 2024$331.35M+11.7%
Q1 FY2024Mar 31, 2024$267.23M-16.7%
Q4 FY2023Dec 31, 2023$167.34M-51.1%
Q3 FY2023Sep 30, 2023$307.20M-26.5%
Q2 FY2023Jun 30, 2023$296.77M-2.1%
Q1 FY2023Mar 31, 2023$320.71M+53.5%
Q4 FY2022Dec 31, 2022$341.97M+92.4%
Q3 FY2022Sep 30, 2022$417.99M+52.5%
Q2 FY2022Jun 30, 2022$303.04M+626.8%
Q1 FY2022Mar 31, 2022$208.98M-26.7%
Q4 FY2021Dec 31, 2021$177.76M-4.6%
Q3 FY2021Sep 30, 2021$274.06M+6.3%
Q2 FY2021Jun 30, 2021$41.70M-77.2%
Q1 FY2021Mar 31, 2021$285.00M+4.4%
Q4 FY2020Dec 31, 2020$186.27M+112.2%
Q3 FY2020Sep 30, 2020$257.89M-23.6%
Q2 FY2020Jun 30, 2020$182.52M+22.6%
Q1 FY2020Mar 31, 2020$272.97M+35.0%
Q4 FY2019Dec 31, 2019$87.80M-59.7%
Q3 FY2019Sep 30, 2019$337.50M+52.4%
Q2 FY2019Jun 30, 2019$148.85M-22.5%
Q1 FY2019Mar 31, 2019$202.25M+20.8%
Q4 FY2018Dec 31, 2018$218.10M+6.6%
Q3 FY2018Sep 30, 2018$221.48M+17.2%
Q2 FY2018Jun 30, 2018$191.97M+42.1%
Q1 FY2018Mar 31, 2018$167.36M+1.7%
Q4 FY2017Dec 31, 2017$204.56M+13.2%
Q3 FY2017Sep 30, 2017$188.90M–
Q2 FY2017Jun 30, 2017$135.09M–
Q1 FY2017Mar 31, 2017$164.54M–
Q4 FY2016Dec 31, 2016$180.70M–

More Jazz Pharmaceuticals figures

See a number that looks wrong?